Down 4.7% today, more than its biotech peers' 1.4%; no story names it yet.
Behind the market
Down 79% over five years while the S&P 500 rose 72%.
“The decrease was primarily attributable to ZOLGENSMA royalty revenues”
RGNX's Quality Score fell 3 points on Tue, Nov 10, to -6. Buying slipped from its highest in 20 days (4 chart checks stopped).
Follow RGNX's trial news. Pro members can get an alert when REGENXBIO files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | 26.3% more shares than a year ago |
| Latest filing | 8-K, Nov 5 |
TodayNo story names it yet.
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
After its last 4 reports it closed -9.8% on average, higher 1 of 4 times.
$251M in cash
Director Gregory Austin Ciongoli bought 102,603 shares on Aug 27. 4 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
RGNX is #217 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 217 |
Expected to report Thu Mar 4, before the open (in 114 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $9.2M, 69% less than a year ago; a loss of $0.62 a share, from $1.20.
“The decrease was primarily attributable to ZOLGENSMA ® royalty revenues, which decreased by $21.2 million due primarily to the expiration of licensed patents in the U.S. in January 2026.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| License and service | $5.2M | $104M | $23.6M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
| Measure | Figure |
|---|---|
| Cash runway | into late Q4 2027 |
“The increase was primarily attributable to clinical trial expenses for RGX-202.”
From its results filing (SEC filing · Nov 5)
Sales grew 2% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 6.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | -6.6% | -4.3% | not yet |
| Aug 6, 2026 | +7.4% | +7.4% | +3.9% |
| May 14, 2026 | -19.5% | -37.8% | -40.5% |
Sales grew in three of the last seven years, to $170M in 2025. It made a profit in two of the eight years.
RSI 52.5, MACD above signal, below both averages. Not scored.
One insider bought $949K across 2 filings, and one insider sold $689K across 2 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: RGNX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
“Not only must we compete with other companies that are focused on gene therapy products technology and other gene therapy platforms, but any products that we may commercialize will have to compete with existing therapies and new therapies that may become available in the future.”
RGNX scores -6 today, which Breakaway calls Poor. It is #217 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 79% over five years while the S&P 500 rose 72%. Shares: 26.3% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
RGNX scores -6 today, which Breakaway calls Poor (below zero). That is #217 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RGNX's -6.
One insider bought $949K across 2 filings, and one insider sold $689K across 2 filings, in the last 6 months. The newest is Gregory Austin Ciongoli, Director, who bought $500K on Aug 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.